Propafenone

Czech version

Authors: Vítovec J.; Špinarová L.; Špinar J.
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
Published in: Kardiol Rev Int Med 2019, 21(4): 221-222

Overview

Propafenone hydrochloride is a potent antiarrhythmic agent effective in both supraventricular and ventricular arrhythmias. According to the Vaughan Williams classification, it belongs to class Ic antiarrhythmic medication, but with concurrent betareceptor antagonist activity. Propafenone is used in oral and intravenous form for the restoration of sinus rhythm in atrial fibrillation, orally for the prevention of recurrences of atrial fibrillation and the maintenance of sinus rhythm or for the suppression of ventricular ectopy. Propafenone is generally indicated in patients without structural heart disease and is unsuitable for heart failure.

Keywords:

atrial fibrillation – propafenone – antiarrhythmic drug – ventricular ectopy – structural heart disease

Sources

1. Lefflerová K. Propafenon. Remedia 2017; 27: 494–497.

2. Stoschitzky K, Stoschitzky G, Lercher P et al. Propafenone shows class Ic and class II antiarrhythmics effects. Europace 2016; 18(4): 568–571. doi: 10.1093/ europace/ euv195.

3. Novák M, Lábrová R, Nováková Z et al. Antiarytmika: 125–158. In: Vítovec J, Špinar J, Špinarová L a kol. Farmakoterapie kardiovaskulárních onemocnění. 3. vyd. Praha: Grada 2017.

4. Bytešník J. Antiarytmická farmakologická léčba fibrilace síní. Remedia 2011; 21(2): 140–146.

5. Brugada J, Katritsis DG, Arbelo E et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J 2019: pii: ehz467. doi: 10.1093/ eurheartj/ ehz467.

6. Čihák R, Haman L, Táborský M. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2016; 58(6): 636–683. doi: 10.1016/ j.crvasa.2016.11.005.

Labels

Paediatric cardiology Internal medicine Cardiac surgery Cardiology

News in the treatment of dyslipidaemia

The CAROLINA study and its impact on clinical practice

Management of asymptomatic arrhythmias – a shortened and commented consensus document of the European Heart Rhythm Association (EHRA)

Indapamide is not only a diuretic

Nitrendipine – a modern calcium channel blocker

SGLT2 or when metformin is not enough

Balloon counterpulsation, ECMO and heart transplant within 24 hours in a patient in cardiogenic shock

Vzpomínka na prof. MU Dr. Vladislava Krutu, DrSc. dlouholetého přednostu Fyziologického ústavu MU Brno

Article was published in

Cardiology Review

2019 Issue 4